(MENAFN- Market Press Release) February 29, 2024 3:52 am - Sentro Pharma is a well-known top pharmaceutical industry in Chhattisgarh. The firm is happy to announce the top 5 most anticipated drug launches of 2024 in its most recent collection of contemporary medications in India.
"Sentro Pharma's new pharmaceutical products launch in India.
Sentro Pharma, a renowned pharmaceutical company committed to improving healthcare globally, is pleased to announce the much-awaited launch of its latest collection of modern medicines in India. Sentro Pharma highlights the top 5 most anticipated drug launches of 2024 innovative medications that are intended to change the standard of care in an array of fields of therapy, with an emphasis on fulfilling urgent healthcare requirements while optimizing patient outcomes.
The primary product featured in this innovative release is rosuvastatin 40mg, an effective medication designed to lower the risk of cardiovascular events and combat high cholesterol levels. With a strong research basis and significant clinical trial expertise, rosuvastatin 40mg provides patients with an accurate way to regulate cholesterol levels to improve heart health, leading them to live longer, healthier lives.
A recent addition to the product range is Voglisentro 0.3 MD Tablet, an effective formulation developed to successfully treat respiratory disorders. The Voglisentro 0.3 MD Tablet is an important step in respiratory care, providing those with a greater feeling of comfort and wellness. It is intended to provide prompt relief from symptoms such as dyspnea and bronchospasm.
We also offers Parosen 12, a cutting-edge drug meant to treat hypertension and reduce associated symptoms. Parosen 12 is a core ingredient in the treatment of high cholesterol levels owing to its powerful yet safe formulation, ensuring patients a reliable means to maintain appropriate blood pressure control and enhance overall cardiovascular health.
Additionally, we offers Telmisartan 80 mg/Glimsentro-PG1, an original combination of prescriptions that is carefully developed for managing type 2 diabetes and hypertension at the exact same time. By deploying the proven hypertension characteristics of telmisartan alongside the distinctive glucose-lowering effects of Glimsentro-PG1, this drug offers patients an integrated strategy to treat both illnesses at the same time. This could speed up the process and improve the effectiveness of therapy.
Sentro Pharma's Naveen Rao, Founder, said, ""We are delighted to introduce these contemporary drugs to the Indian market."" ""At Sentro Pharma, we are motivated by an unchanging belief in development and effectiveness, and these emerging offerings reinforce our genuine dedication to enhancing the treatment of patients as well as advancing healthcare results.""
We continues to affirm its leadership in the pharmaceutical industry by launching these outstanding pharmaceuticals that solve neglected health needs and allow individuals to live better, more rewarding lives. Sentro Pharma is lifelong in its goal to greatly enhance the health and well-being of people worldwide by upholding its values of rational thinking and compassionate care."
About Us:
"Sentro Pharma & Healthcare, incorporated in 2022, is a young, innovative, and value-driven top pharmaceutical industry in Madhya Pradesh. It is built on trust and faith, with a focus on quality and innovation.
Designed, Developed, and Distributed by Doctors!!
We believe in providing the highest-quality medicines at affordable prices. Our product range includes a wide variety of ethical drugs in multiple finished dosage forms. Innovation and purity, or quality, are the core moto of Sentro Pharma & Healthcare. With our founder, Dr. Naveen Rao, we aim to emerge as an innovative healthcare company by creating and delivering high-quality products to the medical fraternity at an affordable price."
MENAFN01032024003520003262ID1107920337
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.